• Publications
  • Influence
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.
Age, grade, stage, and functional status predict survival in patients with PNETs, and survival has improved over time, but this is not explained by earlier diagnosis or stage migration.
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
Hematic resection for metastatic neuroendocrine tumors is safe and achieves symptom control in most patients, and is justified by its effects on survival and quality of life.
Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation +
One‐hundred‐ninety‐four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high‐dose (6000 rads)
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
The anaplastic neuroendocrine tumor is strongly responsive to therapy with combined etoposide and cisplatin and should be evaluated for this possibility with appropriate immune staining or electron microscopy.
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study.
RFA of painful osteolytic metastases provides significant pain relief for cancer patients who have failed standard treatments, with a 2-unit drop considered clinically significant.
Factors associated with progression of carcinoid heart disease.
Serotonin is related to the progression of carcinoid heart disease, and the risk of progressive heart disease is higher in patients who receive chemotherapy than in those who do not, according to a retrospective study conducted to identify such factors.
Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation.
RF ablation of painful osteolytic metastases is safe, and the relief of pain is substantial, according to analysis of the primary end point and paired comparison procedures.
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
OnceOctreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SCoctreotide, and a starting dose of 20 mg of octanotide LAR is recommended.
Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.
The epidemiology, prognosis, and established and novel prognostic markers of PETs are reviewed and patients with completely resected tumors generally have a good prognosis.
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Pazopanib seems to represent a promising therapeutic option for patients with advanced differentiated thyroid cancers, and the correlation of the patient's response and pazobanib concentration during the first cycle might indicate that treatment can be individualised to achieve optimum outcomes.